FIELD: medicine; oncology.
SUBSTANCE: determine clinical symptoms and risk factors from the anamnesis of life and clinico-laboratory indicators, namely indicators: age, level of prostates-specific of an antigen in blood serum (BSA), degree of differentiation of a tumour, duration of disease prior to the beginning of treatment on which sizes carry out the prognosis. In addition perform an estimation of the general condition of the patient on the ECOG scale and establish gradation and numerical value of risk factors. Then define prognostic factors F1 and F2 under formulas: F1=-0.68-0.5•X1+0.13•X2+0.93•X3+0.62•X4; F2=-2.97+1.17•X1-0.3•X2-2.17•X3-1.45•X4; and at F1 is more than F2, life expectancy of the patient in months (yF2 define under the formula: yF1=0.29•X5-2.12•X2+0.56•X1+1.86•X3-0.02•X1 2+0.0006•X4 2, and at F2 is more than F1, life expectancy of the patient in months (yF2) define under the formula: yF2=160.19-0.94•X5-17.00•X2-0.36•X1, where X1.2...5 - gradation and numerical value of risk factors, Thereat, X1 - duration of disease - time from occurrence of symptoms of disease to the reference of the patient to the doctor, in months; X2 - a tumour differentiation: G0 - highly differentiated tumour=0, G1 - differentiated tumour=1, G2 - is moderate-differentiated tumour=2, G3 - low-grade tumour=3, G4 undifferentiated tumour=4; X3 - the general condition of the patient on the ECOG scale: activity of the patient is unlimited=0, restriction by kinds of the activity, demanding efforts=1, walking and capable itself to serve, but incapable to carry out any job=2, is limited capability for self-service=3, are completely incapable to any kind of activity=4; X4 - level of the BSA in ng/ml, X5 - age, years.
EFFECT: increase of accuracy of the prognosis at the expense of definition of life expectancy of patients in months, and it is simple in execution.
4 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD OF PREDICTING OF LIFE EXPECTANCY OF PATIENTS WITH LOCAL CANCER OF PROSTATE | 2007 |
|
RU2341197C1 |
METHOD FOR PREDICTION OF RESPONSE TIME TO ANDROGEN DEPRIVATION THERAPY IN PATIENTS WITH PROSTATE CANCER | 2019 |
|
RU2688181C1 |
METHOD FOR LIFESPAN EVALUATION IN PATIENTS WITH LOCALLY ADVANCED AND DISSEMINATED RENAL CELL CARCINOMA | 2009 |
|
RU2405150C1 |
METHOD FOR PREDICTING RISK OF DEVELOPING LYMPHOGENOUS COMPLICATIONS AFTER RADICAL PROSTATECTOMY WITH PELVIC LYMPHADENECTOMY | 2021 |
|
RU2752949C1 |
METHOD OF PREDICTION OF POSTOPERATIVE CARDIAC ISCHEMIC COMPLICATIONS IN A PATIENT WITH LUNG CANCER | 2022 |
|
RU2798781C1 |
METHOD FOR PREDICTING THE DURATION OF A RELAPSE-FREE PERIOD IN PATIENTS WITH RESECTABLE THRICE-NEGATIVE BREAST CANCER | 2021 |
|
RU2780922C1 |
METHOD OF PREDICTING LIFE DURATION OF PATIENTS WITH EXTENSIVE KIDNEY CANCER COMPLICATED BY VENOUS INVASION | 2008 |
|
RU2373864C1 |
METHOD OF PREDICTING SEVERITY OF BRONCHIAL ASTHMA COURSE | 2012 |
|
RU2486870C1 |
METHOD FOR PREDICTION OF ESSENTIAL ARTERIAL HYPERTENSION IN ADOLESCENTS WITH SLEEP DISTURBANCE | 2009 |
|
RU2417737C1 |
METHOD FOR PREDICTING THE DEVELOPMENT OF A CHRONIC COURSE OF A DEPRESSIVE DISORDER | 2017 |
|
RU2657193C9 |
Authors
Dates
2008-12-10—Published
2007-06-20—Filed